SW 682
Alternative Names: SW-682Latest Information Update: 20 Jun 2025
At a glance
- Originator SpringWorks Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Mesothelioma; Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 23 Oct 2024 Pharmacodynamics data from preclinical trial in Head and neck cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)
- 23 Oct 2024 Pharmacodynamics data from preclinical trial in Head and neck cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)